Source comparison
TB-500 Research Supplement Stack: Synergy Comparison
TB-500 + BPC-157 Complementary: TB-500 enhances actin migration, BPC-157 modulates VEGF and growth factor expression independently Stagger by 6–8 hours to avoid hepatic competition Enhanced tissue repair with independent angiogenic and fibroblast activation pa
This comparison does not assign a generated winner or score.
- TB-500 + BPC-157
- Complementary: TB-500 enhances actin migration, BPC-157 modulates VEGF and growth factor expression independently
- Stagger by 6–8 hours to avoid hepatic competition
- Enhanced tissue repair with independent angiogenic and fibroblast activation pathways
- Both stable in bacteriostatic water for 28 days at 2–8°C; store separately to prevent cross-contamination
- Gold-standard pairing for wound healing research—minimal receptor overlap, proven independent pathway activation
- TB-500 + Ipamorelin
- Synergistic: TB-500 provides baseline angiogenesis, Ipamorelin pulses IGF-1 for intermittent mTOR activation
- Administer Ipamorelin 12 hours after TB-500 to separate eNOS and IGF-1 peak timing
- Sustained tissue repair with periodic growth hormone-mediated protein synthesis
- Ipamorelin degrades within 14 days post-reconstitution; TB-500 remains stable for 28 days—prepare Ipamorelin in smaller batches
- Effective for protocols requiring both vascular and muscular regeneration—timing discipline critical
- TB-500 + CJC-1295 (no DAC)
- Moderate synergy: TB-500 actin binding + CJC-1295 GH release; both elevate IGF-1 but through different mechanisms
- Stagger by 24 hours to prevent overlapping IGF-1 peaks that cause receptor downregulation
- Enhanced recovery with sustained IGF-1 elevation; risk of receptor fatigue after 6–8 weeks
- CJC-1295 (no DAC) stable 21 days; TB-500 stable 28 days—align reconstitution schedules to minimise waste
- Useful for long-term recovery studies—requires mid-protocol washout to restore receptor sensitivity
- TB-500 + MK-677
- High synergy: TB-500 angiogenesis + MK-677 continuous GH secretion creates compounding IGF-1 environment
- MK-677 (oral) taken 8–10 hours before TB-500 injection to offset GH pulse timing
- Maximal angiogenic and regenerative signalling; highest risk of pathway saturation
- MK-677 is orally stable as tablets; TB-500 requires standard peptide refrigeration—no interaction risk
- Most potent combination for tissue repair research but demands strict cycle timing to avoid receptor exhaustion
- TB-500 + Sermorelin
- Minimal synergy: both elevate angiogenic factors but through redundant pathways (VEGF/FGF overlap)
- No advantage to staggering—effects are redundant rather than complementary
- Marginal improvement over TB-500 alone; sermorelin adds cost without proportional benefit
- Both stable under identical storage conditions—but stacking offers negligible research value
- Not recommended—use sermorelin OR TB-500, not both, unless testing pathway redundancy is the research goal